On July 18th, GenSci announced that New Drug Application of its Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection has been accepted by the Center for Drug Evaluation, NMPA. This product is a long-acting recombinant human follicle-stimulating hormone intended for female assisted reproductive therapy(ART), which will potentially enhance convenience and patient compliance. Its safety and efficacy has been confirmed in the research.  

As a pioneer in women’s health, GenSci is committed to offering a diverse portfolio covering women life-cycle from assisted reproduction and menopausal support to the management of common gynecological conditions，delivering superior innovative solutions for women's health.

Currently, GenSci has multiple innovative products on the market, including the GnRH agonist triptorelin, GnRH antagonist cetrorelix, follicle-stimulating hormone (FSH), and JinSaixin® progesterone injection (II), collectively offering comprehensive care for women's health. The accepted product today is another key product of the diverse portfolio covering women's life-cycle health management.